About StemoniX
StemoniX is a company based in San Diego (United States) founded in 2014 was acquired by Cancer Genetics in August 2020. StemoniX has raised $33.7 million across 11 funding rounds from investors including Cancer Genetics, Brightstone Venture Capital and Seed San Diego. StemoniX operates in a competitive market with competitors including Slingshot Bioscience, InterAx Biotech, ZoBio, Magnitude Biosciences and Signal Pharmaceuticals, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$33.7 M (USD)
in 11 rounds
-
Latest Funding Round
$100 K (USD), Series B
May 15, 2020
-
Investors
Cancer Genetics
& 10 more
-
Employee Count
Not available
-
Acquired by
Cancer Genetics
(Aug 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of StemoniX
StemoniX has successfully raised a total of $33.7M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $100 thousand completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in StemoniX
StemoniX has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Cancer Genetics, Brightstone Venture Capital and Seed San Diego.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
VC firm investing in early-stage mediatech & technology startups
|
Locked | Locked | Locked |
Investor details for StemoniX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by StemoniX
Investment portfolio details for StemoniX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - StemoniX
Detailed financials for StemoniX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stemonix Comparisons
Peer comparison for StemoniX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of StemoniX
StemoniX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Slingshot Bioscience, InterAx Biotech, ZoBio, Magnitude Biosciences and Signal Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Next-generation synthetic cells are developed for diagnostics and therapeutics.
|
|
| Locked | Locked | Locked |
Mutated arrestins are employed as biosensors for GPCR drug discovery.
|
|
| Locked | Locked | Locked |
Provider of fragment-based drug discovery services
|
|
| Locked | Locked | Locked |
Cell-free in vitro assays are supplied to drug discovery firms.
|
|
| Locked | Locked | Locked |
Small molecule drugs regulating disease-associated genes are developed.
|
Detailed competitors of StemoniX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stemonix
Complete news archive for StemoniX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about StemoniX
StemoniX was founded in 2014 and raised its 1st funding round 1 year after it was founded.
StemoniX is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ping Yeh is the current CEO of StemoniX.
StemoniX is a funded company, having raised a total of $33.7M across 11 funding rounds to date.
StemoniX is a regenerative medicine company engages in the production, growth, and development of stem cell and stem cell technologies. Makes plates of human tissue for custom drug discovery that is enabled by a rapid, low cost high volume process for growing and differentiating stem cells. Technology developed by company will allow pharma companies and drug researchers to test their drug efficacy, toxicity before lengthy clinical trials.
StemoniX's top competitors include Magnitude Biosciences, Slingshot Bioscience and Sequence Bio.
StemoniX has 11 investors. Key investors include Cancer Genetics, Brightstone Venture Capital, Seed San Diego, Keshif Ventures, and Mayo Clinic Business Accelerator.